308 results about "Isolated cell" patented technology

Provided herein are methods and compositions disclosing an approach that combines single nuclear RNA-seq (snRNA-seq) with spatial transcriptomics. The methods include processing and analyzing multiple analytes in a biological sample, and utilizes multiple substrates, one having a spatial array having a plurality of capture probes, each having a capture domain and a spatial barcode. The methods can be used to detect location of both nucleic acid and protein analytes. The methods also include isolating cells and / or nuclei from a sample and determining analyte expression in the isolated cells and / or nuclei.

The invention relates to the technical field of carbon ion radiotherapy relative biological effects, and discloses a cell survival rate prediction method and system based on Monte Carlo simulation carbon ion spectrum distribution. The method comprises the following steps: collecting experimental data of isolated cells to construct a cell database; based on the energy range of carbon ion radiotherapy particles and the type of secondary particles, a monte carlo method is used to construct a monoenergetic particle DNA damage database. And then constructing a cell survival rate prediction model based on DNA damage repair, and fitting cell radiation specificity parameters of the model based on a cell database to accurately reflect the radiation sensitivity of the cells. Then on the basis of the monoenergetic particle DNA damage database, the mixed beam DNA damage characteristics are determined in a dose weighting mode, the mixed beam DNA damage characteristics are input into the model subjected to parameter fitting to predict the cell survival rate, the secondary particle biological effect is considered, and the prediction accuracy of the clinical carbon ion beam relative biological effect can be improved.

Anti-CD90 antibodies, binding fragments, and uses thereof are described. The provided antibodies and binding fragments can be used to isolate CD90 cells or to target such cells ex vivo or in vivo for a research, a diagnostic, or a therapeutic purpose. Anti-CD90 antibodies and binding fragments thereof can also be used in engineered formats to create multi-domain binding molecules, antibody conjugates, recombinant receptors, or within a recombinant protein to pseudotype viral vectors.

The invention provides an applicable population screening method and application of a glioma dry-like cell sensitized DC vaccine, peripheral blood of a patient before and after inoculation of the glioma dry-like cell sensitized DC vaccine is obtained, mononuclear cells are extracted, CD8 + T cells are respectively separated from the mononuclear cells through a magnetic bead sorting method, and the CD8 + T cells are separated from the mononuclear cells. The method comprises the following steps: uniformly inoculating CD8 < + > T cells into an ELISPOT cell culture plate coated with an IFN-gamma antibody for culture, respectively setting an experimental group and a positive control group for culture, adding A2B5 < + > glioma cell lysis buffer into the experimental group and adding phytohemagglutinin into the positive control group, and carrying out ELISPOT staining on the cultured cells to obtain the secretion amount of FN-gamma before and after treatment of a patient. According to the secretion amount of the FN-gamma, patients with specific immune response to the glioma dry-like cell sensitization DC vaccine are screened, so that the glioma dry-like cell sensitization DC vaccine is conveniently popularized and applied, and the immune mechanism of the glioma dry-like cell sensitization DC vaccine is researched.

The invention discloses a monoclonal goat intramuscular precursor fat cell immortalized cell line as well as a preparation method and application thereof, and relates to the field of immortalized cells. The method comprises the following steps: acquiring precursor fat cells in primary goat muscle; the method comprises the following steps: infecting precursor adipocytes in primary goat muscle with a lentivirus carrying SV40-T, and adding puromycin to screen positive cells infected with the lentivirus carrying SV40-T; a limited dilution method is used, the screened positive cells are laid on a plate according to one cell per hole, and the monoclonal goat intramuscular precursor fat cell strain is obtained after culture; and carrying out amplification culture on the monoclonal goat intramuscular precursor fat cell strain to obtain the immortalized cell line of the monoclonal goat intramuscular precursor fat cell. According to the immortalized cell line obtained by the method, while the morphology and the function of the precursor fat cells in the goat muscle are ensured, the passage generation number of the cells is remarkably increased, and the cells do not need to be repeatedly sampled and separated, so that the same genetic background of the cells is ensured, and the cost and the workload are greatly saved.

The invention discloses a preparation method of a homologous tumor cell and American ginseng composite exosome, and belongs to the field of functional medical materials and nanotechnologies, and the preparation method comprises the following steps: S1, separating a U87 cell exosome from a U87 cell by using a continuous ultracentrifugation method, and preparing U87-Exos for later use; s2, separating American ginseng exosomes from American ginseng rhizomes by using a continuous ultracentrifugation method, and preparing AG-Exos for later use; s3, the U87-Exos obtained in the step S1 and the AG-Exos obtained in the step S2 are subjected to extrusion compounding, and U87 / AG-Exos is prepared; s4, temozolomide and resveratrol are dissolved in a solvent and mixed with the U87 / AG-Exos obtained in the step S3, and then the mixed solution is subjected to ultrasonic treatment. According to the exosome preparation method, a medicine delivery system based on homologous tumor cell composite Exos is prepared, TMZ and RES are jointly delivered and used for treating GBM, the medicine delivery system is based on the concept of traditional Chinese medicine combination therapy, the limitation of traditional chemotherapy is overcome, and a promising strategy is provided for treating GBM.

Methods for generating human vascular leptomeningeal cells (VLMCs) from human oligodendrocyte progenitor cells (OPCs) are provided using chemically-defined culture media that allow for generation of differentiated cells in a 34-day culture protocol. Methods of generating human VLMCs from human pluripotent stem cells using chemically-defined culture media in a 40 day culture protocol are also provided. Culture media, isolated cell populations, and kits are also provided.

An isolated cell having a central memory T-lymphocyte (Tcm) phenotype, the cell being tolerance-inducing cell and capable of homing to the lymph nodes following transplantation, the cell being transduced to express a cell surface receptor comprising a T cell receptor signaling module is described. Methods of generating same and using same are also described.

The invention relates to the technical field of biopharmaceutical equipment, in particular to a sterile culture method and a sterile culture system. The sterile culture system comprises a cell preparation device, an incubator and a cell culture device, the cell preparation device comprises a preparation chamber, and a first sealing valve is arranged on the side wall of the preparation chamber; the incubator is provided with a culture chamber, a second sealing valve is arranged on the side wall of the culture chamber, and the second sealing valve is used for being matched with the first sealing valve, so that the incubator and the cell preparation device are in sealed butt joint or sealed separation; the cell culture device is used for accommodating the culture box, supplying power and gas to the culture box and controlling the cell growth environment in the culture box. As the cells always grow in the sterile environment, the pollution risk is low, frequent sterilization is not needed, the normal growth of the cells is prevented from being influenced by frequent sterilization, the culture time is saved, and the cell preparation and culture efficiency is high.

The invention provides a multi-channel viscoelastic micro-fluidic chip, a manufacturing method and a method for separating MCF-7 cells. The multi-channel viscoelastic micro-fluidic chip comprises a first multi-stage shunting module, a pipette, a second multi-stage shunting module, a single-stage viscoelastic micro-fluidic sub-module and a third multi-stage shunting module, the first multi-stage shunting module is connected with one inlet of the single-stage viscoelastic micro-fluidic sub-module through a pipette; the second multi-stage shunting module is connected with the other inlet of the single-stage viscoelastic micro-fluidic sub-module; and the outlet of the single-stage viscoelastic micro-fluidic sub-module is connected with the third multi-stage shunting module. According to the method, the PEO solution is used as sheath fluid, and the action of elastic force is introduced to cells, so that CTC can be directly separated from undiluted human blood in an ultrahigh-flux manner, and the limitation that erythrocytes need to be split and a blood sample needs to be diluted by dozens of times before cell separation in traditional inertial microfluidics is broken through; and the complexity of operation and the risk of sample pollution are reduced.

The present disclosure relates to a cell obtaining method for creating NFT based on a cell image. The cell obtaining method includes the steps of separating a cell from a biological sample, obtaining a stem cell by treating the cell with a dedifferentiation inducer, differentiating the stem cell, acquiring an image of the differentiated cell; and converting the image of the differentiated cell into an NFT image, and creates the NFT using a vital image in a simple and easy way through non-invasive and non-medical procedures.

Fusion polypeptides are provided and comprise at least two ligand binding domains and a fragment crystallizable (Fc) region of immunoglobulin G (IgG). The ligand binding domains include an amino acid sequence selected from the group consisting of SEQ ID NOS: 1-25 and / or one of the at least two ligand binding domains binds modulates B cell activity while the other modulates T cell activity. Isolated nucleic acids, vectors, and isolated cells encoding or including the fusion peptides are further provided. Pharmaceutical compositions include the fusion peptides and a pharmaceutically-acceptable vehicle, carrier, or excipient. Methods of treating Sjögren's Syndrome and / or Systemic Lupus Erythematosus are also provided and comprise administering to a subject in need thereof the fusion polypeptide including the two ligand binding domains and the Fc region of IgG.

The invention discloses an application of a protoplast CUAmp; the invention discloses a high-throughput method for detecting a transcription factor recognition motif by using a Tag technology. The method comprises the following steps: 1) cutting up plant leaves, soaking the cut plant leaves in enzymatic hydrolysate, and separating cells, so that rice powder is completely soaked in the enzymatic hydrolysate; 2) after enzymolysis, wrapping filter residues with gauze, and extruding the filter residues to collect protoplast cells; (3) adding the protoplast cells into a centrifugal tube containing plasmids, instantaneously transferring the plasmids into the cells, and expressing genes transferred by the plasmids; (4) adding a GFP antibody, a secondary antibody and a Tn5 transposon, recovering the DNA combined with the GFP antibody, and carrying out subsequent NGS library building; 5) performing high-throughput sequencing to obtain a transcription factor sequence, and performing biological information analysis to obtain a transcription factor combined motif; and 6) verifying the interaction of the transcription factor and the recognition motif by using an EMSA method.

The disclosure relates to method and kits for highly specific detection and quantification of extracellular vesicles (EVs) by targeting at least two EV surface markers using binding reagents. The binding reagents contain hybridisation sequences and primer binding regions, the hybridisation sequences are ligated and amplified using primers. The disclosure further relates to methods and kits for isolating EVs using capture entities, splint entities and staple entities wherein the capture entity comprises a labile linkage.

The invention relates to the field of medical image processing, and particularly discloses a TLS structure sketching system and method based on artificial intelligence, and the method comprises the steps: S1, image preprocessing: carrying out the standardization processing of an input HE staining section image, firstly separating cell nucleus and cytoplasm staining components through a color deconvolution algorithm, and highlighting the nucleoplasm contrast of lymphocytes; then strengthening the cell contour boundary by adopting an edge detection algorithm, and connecting the fracture edge through morphological operation to form a continuous and clear cell boundary mask; s2, morphological feature extraction: performing single cell segmentation based on the preprocessed image, and extracting geometric features and texture features of each cell; through machine learning model training, distinguishing lymphocytes and non-lymphocytes according to the characteristics, and generating a lymphocyte distribution probability graph; and S3, preliminarily identifying the aggregated area. By adopting the technical scheme of the invention, the TLSs differentiation stage can be identified, and the identification accuracy can be improved by combining morphological characteristics and spatial distribution characteristics.

Provided is a method and apparatus for cell staining without cell loss, and more particularly, to a method and apparatus for cell staining without cell loss during treatment of a staining reagent or washing reagent by immobilizing cells to be analyzed in a phase change material before staining. A method for cell staining without cell loss may effectively prevent cell loss during staining and analysis of rare cells that are becoming important in clinical diagnosis, and thus may facilitate observation, analysis and diagnosis thereby even with a trace amount of sample. In addition, as the method for cell staining without cell loss allows immobilization of cells, it makes discrimination and isolation of single cells easy, and may be effectively used in analysis of the isolated cells.

The present invention relates to a method for producing a skin tissue model, comprising: (a) isolating and culturing fibroblasts and keratinocytes from skin tissue; (b) preparing a bioink composition for a dermal layer and a bioink composition for an epidermal layer, the bioink composition containing the isolated cells; and (c) producing a skin tissue model using the bioink composition for a dermal layer and the bioink composition for an epidermal layer.

The present invention relates to the chromatographic isolation of a target cell or another complex biological material, in particular by column chromatography such as affinity chromatography or gel permeation chromatography. The invention employs a receptor binding reagent that binds to a receptor molecule that is located on the surface of a target cell. The invention in general provides novel methods for the traceless isolation of biologic materials such as cells, cell organelles, viruses and the like. The invention also relates to an apparatus for the isolation of cells and other complex biological materials.

Methods for generating mature somatostatin+ interneurons from human forebrain neural progenitor cells are provided using chemically-defined culture media in a two-stage culture protocol. The mature somatostatin+ interneurons are generated from medial ganglionic eminence neural progenitor cells (MGE-NPCs), which themselves are differentiated from pluripotent stem cells. Culture media, isolated cell populations and kits are also provided.

Formulations of gas-filled microvesicles comprising a ligand, which may advantageously be used in methods for separating cells or biological materials. The formulations comprise a phospholipid and a suitable mixture of a pegylated phospholipid and of a pegylated phospholipid comprising a ligand.

To provide: a cell culture vessel that can achieve both detachability and proliferation ability, that is, can facilitate cell detachment without reducing the proliferation ability of cells; and a cell detachment method using the cell culture vessel, provided is a cell detachment method of detaching, through use of a culture vessel having a periodic recess / protrusion pattern on a culture surface, comprising a detachment step of: causing a vibrating unit in which, when an observation image of a cross section perpendicular to the culture surface is obtained, a length Lcp of a contour of the cell on the culture surface side in a measurement region of the observation image and a length Lf of the measurement region in a direction parallel to the culture surface satisfy Lcp>Lf; and transmitting the ultrasonic vibration to the cell, to thereby detach the cell from the culture surface.

The invention relates to the technical field of biology, and discloses a construction method of a gastric cancer organoid culture system, which comprises the following steps: preparation of a conditioned medium: culturing L-WRN cells and collecting the conditioned medium; preparing a gastric cancer organoid culture medium, and mixing the conditioned culture medium, the basic culture medium, a plurality of growth factors and additives; and extraction and culture of organoid: separating cells from gastric cancer tissues, mixing the cells with matrigel, and culturing by using the prepared culture medium. According to the method, the repeatability and the stability of the organoid model are improved, the response consistency of the organoid in drug screening is improved, and the reliability of the model in disease mechanism research and personalized medical application is guaranteed.

A method of generating cells of the T cell lineage is provided that involves culturing a sample comprising stem cells or progenitor cells with an engineered Notch ligand conjugated to a suspension support and isolating cells of the T cell lineage. In one embodiment, the cells of the T-cell lineage are progenitor T cells or mature T cells. Compositions, kits and uses thereof are also provided.

Described herein is an isolated cell comprising a recombinant T cell receptor (TCR) and a TCR pathway-dependent reporter, wherein the recombinant T cell receptor is specific for a disease-associated antigen bound to an MHC molecule. Also described is an assay for the isolated cell for determining the function or efficacy of a peptide-major histocompatibility complex (pMHC) (pMHC-NP) coupled to a nanoparticle, which can be used as a drug for treating autoimmune diseases or cancer.

The present application relates to a filter system that can be used as a clarification filter / depth filter for clarification of cell cultures prior to chromatography and / or ultrafiltration for protein purification, the invention also relates to a method for separating cells and other contaminants from a fluid comprising one or more target components by employing the filter system of the present application.

To provide an isolated cell capable of regulating cough.SOLUTION: The problem is solved by an isolated laryngeal PCC expressing Calhm3 protein.SELECTED DRAWING: None

The present application relates to (i) a variant adeno-associated virus (AAV) capsid polypeptide comprising a peptide insertion in the variable region IV or in the variable region VIII relative to a wild-type AAV capsid polypeptide, wherein the peptide insertion comprises an amino acid sequence selected from the group consisting of SEQ ID NOs:1-29 or an amino acid sequence having at least 70% sequence identity thereto, (ii) an isolated nucleic acid encoding the aforementioned variant polypeptide, (iii) a recombinant polynucleotide comprising the aforementioned nucleic acid, and (iv) an isolated cell comprising the aforementioned polypeptide, nucleic acid or recombinant polynucleotide. The present application further relates to (v) an adeno-associated virus (AAV) vector comprising the aforementioned variant polypeptide, (vi) a pharmaceutical composition comprising the aforementioned AAV vector as well as (vii) the use of the aforementioned vector or pharmaceutical composition in preventing or treating an ocular disease. Finally, the present application relates to (viii) a method of delivering a heterologous nucleic acid to a retinal cell and (ix) a method of delivering a heterologous nucleic acid to the eye of a subject.

An apparatus and method for T-cell separation, activation, transduction and expansion. Three-dimensional (3D) bioreactors may be employed that include antibody coatings. Such 3D bioreactors can be employed for T-cell separation from peripheral blood mononuclear cells including attachment of T-cells to the 3D bioreactor surface for activation and transduction by lentivirus vectors to produce CAR T-cells. The CAR T-cells can then be expanded in a separate downstream bioreactor therein providing a scalable automated system.

The invention relates to the technical field of biocompatible compositions, in particular injectable biocompatible compositions. In particular, the invention relates to a particular biocompatible composition comprising a solution and heterogeneous cellular elements suspended in said solution, which elements are selected from isolated cells, cellular microtissues, cell clusters and mixtures thereof, at least two of said cellular elements having a different density and / or size and / or number of cells.

The invention relates to the fields of molecular biology and virology, and provides a method for preparing a specific MHC haplotype-derived cell-binding virus. The method comprises the following steps: firstly, obtaining chick embryos of different haplotypes, separating CEF cells, transiently expressing exogenous fluorescent protein through electrotransfection, then carrying out virus inoculation, carrying out flow sorting to obtain a fluorescent positive cell population carrying MDV, and carrying out quantitative analysis on the cell population to obtain the specific MHC haplotype chicken Marek's Disease Virus (MDV), thereby obtaining the specific MHC haplotype chicken Marek's Disease Virus Marek's Disease Virus Marek's Disease Virus Marek's Disease Virus. And carrying out in-vitro propagation to obtain the purified MDV with a specific haplotype source. The purified virus can provide a test material for related research of haplotype on virus infection, and can be widely applied to in-vitro purification of different cell binding viruses and related research of specific MHC molecule presenting virus peptides. The method disclosed by the invention is beneficial to carrying out related research aiming at the host immune response of the virus and analyzing the hereditary basis of haplotype to MDV differential resistance, and is expected to be applied to preparation of vaccine virus.